Burden of Hypertensive Heart Disease in Iran during 1990-2017: Findings from the Global Burden of Disease study 2017.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
04
2021
accepted:
06
09
2021
entrez:
22
9
2021
pubmed:
23
9
2021
medline:
24
11
2021
Statut:
epublish
Résumé
Hypertension and its consequent end-organ damage including Hypertensive Heart Disease (HHD) are a major concern that impact health, resulting into impairment and reduced quality of life (QOL). The purpose of this study was to describe the burden of HHD in Iran and comparing it with the World Bank upper middle-income countries (UMICs) in terms of disability-adjusted life years (DALY), mortality and prevalence. Using data from the Global Burden of Disease study 2017, we compared the number of DALYs, deaths and prevalence trends for HHD from 1990 to 2017 in all age groups for both sex in Iran, and compared the epidemiology and trends with UMICs and globally. The age-standardized DALY rate for HHD increased by 51.6% for men (95% uncertainty interval [UI] 305.8 to 436.7 per 100,000) and 4.4% for women (95% UI 429.4 to 448.7 per 100,000) in Iran. The age-standardized prevalence of HHD in Iran was almost twice times higher than globally and 1.5-times more than the World Bank UMICs. The age-standardized death rate for HDD increased by 60.1% (95% UI 17.3 to 27.7% per 100,000) for men and by 21.7% (95% UI 25.85 to 31.48 per 100,000) for women from 1990 to 2017. Age-standardized death rate in Iran was 2.4 and 1.9 times higher than globally and UMICs, respectively. The higher prevalence and death rate in Iran in comparison with UMICs and globally should encourage health care provider to perform intensive screening activities in at risk population to prevent HHD and mitigate its mortality.
Sections du résumé
BACKGROUND
Hypertension and its consequent end-organ damage including Hypertensive Heart Disease (HHD) are a major concern that impact health, resulting into impairment and reduced quality of life (QOL). The purpose of this study was to describe the burden of HHD in Iran and comparing it with the World Bank upper middle-income countries (UMICs) in terms of disability-adjusted life years (DALY), mortality and prevalence.
METHODS
Using data from the Global Burden of Disease study 2017, we compared the number of DALYs, deaths and prevalence trends for HHD from 1990 to 2017 in all age groups for both sex in Iran, and compared the epidemiology and trends with UMICs and globally.
RESULTS
The age-standardized DALY rate for HHD increased by 51.6% for men (95% uncertainty interval [UI] 305.8 to 436.7 per 100,000) and 4.4% for women (95% UI 429.4 to 448.7 per 100,000) in Iran. The age-standardized prevalence of HHD in Iran was almost twice times higher than globally and 1.5-times more than the World Bank UMICs. The age-standardized death rate for HDD increased by 60.1% (95% UI 17.3 to 27.7% per 100,000) for men and by 21.7% (95% UI 25.85 to 31.48 per 100,000) for women from 1990 to 2017. Age-standardized death rate in Iran was 2.4 and 1.9 times higher than globally and UMICs, respectively.
CONCLUSIONS
The higher prevalence and death rate in Iran in comparison with UMICs and globally should encourage health care provider to perform intensive screening activities in at risk population to prevent HHD and mitigate its mortality.
Identifiants
pubmed: 34551003
doi: 10.1371/journal.pone.0257617
pii: PONE-D-21-11496
pmc: PMC8457465
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257617Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
PLoS Med. 2009 Apr 28;6(4):e1000058
pubmed: 19399161
Ann Noninvasive Electrocardiol. 2014 Nov;19(6):552-60
pubmed: 24750238
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Ann Intern Med. 2018 Mar 6;168(5):351-358
pubmed: 29357392
JAMA. 2017 Jan 10;317(2):165-182
pubmed: 28097354
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Am Heart J. 2001 Mar;141(3):334-41
pubmed: 11231428
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Lancet. 2018 Nov 10;392(10159):1684-1735
pubmed: 30496102
Heart Fail Clin. 2019 Oct;15(4):531-541
pubmed: 31472888
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Front Endocrinol (Lausanne). 2020 Feb 26;11:42
pubmed: 32174887
Circ Res. 2003 Jul 11;93(1):69-76
pubmed: 12791709
Blood Press Monit. 2010 Jun;15(3):124-31
pubmed: 20305545
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Circulation. 2011 Jan 25;123(3):327-34
pubmed: 21263005
J Hypertens. 2019 Jun;37(6):1148-1153
pubmed: 30624370
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535